Nilotinib (Tasignaƒ, Novartis Pharmaceuticals UK Ltd) is a second generation TKI. It is more effective than imatinib, because it can inhibit several imatinibā€‘resistant BCR-ABL1 mutations.

Nilotinib is approved for:

  • Patients in the chronic phase with newly-diagnosed CML
  • Patients in chronic or accelerated CML phases, who are resistant or intolerant to treatment with previous tried TKIs
Scroll to Top